Efmarodocokin alfa: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 266 patientsc19early.org

Efmarodocokin Alfa for COVID-19

Serious outcome risk
Efmarodocokin Alfa
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−15%
Mortality (1)−15%
RCTs (1)−15%
Late (1)−15%
00.511.5+
← Efmarodocokin
Alfa reduces riskIncreased
risk →
c19early.org
October 2026

Efmarodocokin alfa COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Waters (DB RCT)−15%1.15 · 0.59–2.11death17/13215/134COVASTIL
Late treatment−15%1.15 · 0.60–2.2017/13215/13415% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.69
All studies−15%1.15 · 0.60–2.2017/13215/13415% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6900.511.52+
Rotate screen for more detailsIncrease width for more details
← Efmarodocokin
Alfa reduces
riskEfmarodocokin
Alfa increases
risk →
c19early.org
October 2026

Efmarodocokin alfa COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Waters (DB RCT)−15%1.15 · 0.59–2.1117/13215/134COVASTIL
Late treatment−15%1.15 · 0.60–2.2017/13215/13415% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.69
All studies−15%1.15 · 0.60–2.2017/13215/13415% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6900.511.52+
Rotate screen for more detailsIncrease width for more details
← Efmarodocokin Alfa
reduces riskEfmarodocokin Alfa
increases risk →
c19early.org
October 2026

Efmarodocokin alfa COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Waters (DB RCT)−15%1.15 · 0.59–2.11death17/13215/134COVASTIL
Late treatment−15%1.15 · 0.60–2.2017/13215/13415% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.69
All studies−15%1.15 · 0.60–2.2017/13215/13415% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6900.511.52+
Rotate screen for more detailsIncrease width for more details
← Efmarodocokin
Alfa reduces
riskEfmarodocokin
Alfa increases
risk →
c19early.org
October 2026

Efmarodocokin alfa COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Waters (DB RCT)13%0.87 · 0.65–1.16no recov.132 (n)134 (n)COVASTIL
Late treatment13%0.87 · 0.65–1.16132 (n)134 (n)13% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.35
All studies13%0.87 · 0.65–1.16132 (n)134 (n)13% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.3500.511.52+
Rotate screen for more detailsIncrease width for more details
← Efmarodocokin
Alfa reduces
riskEfmarodocokin
Alfa increases
risk →
c19early.org
October 2026

Efmarodocokin alfa COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Waters (DB RCT)−15%1.15 · 0.59–2.11death17/13215/134COVASTIL
Late treatment−15%1.15 · 0.60–2.2017/13215/13415% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.69
All studies−15%1.15 · 0.60–2.2017/13215/13415% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6900.511.52+
Rotate screen for more detailsIncrease width for more details
← Efmarodocokin
Alfa reduces
riskEfmarodocokin
Alfa increases
risk →
c19early.org
October 2026

Efmarodocokin alfa COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Waters (DB RCT)−15%1.15 · 0.59–2.1117/13215/134COVASTIL
Late treatment−15%1.15 · 0.60–2.2017/13215/13415% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.69
All studies−15%1.15 · 0.60–2.2017/13215/13415% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6900.511.52+
Rotate screen for more detailsIncrease width for more details
← Efmarodocokin Alfa
reduces riskEfmarodocokin Alfa
increases risk →
c19early.org
October 2026

Efmarodocokin alfa COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Waters (DB RCT)−15%1.15 · 0.59–2.11death17/13215/134COVASTIL
Late treatment−15%1.15 · 0.60–2.2017/13215/13415% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.69
All studies−15%1.15 · 0.60–2.2017/13215/13415% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6900.511.52+
Rotate screen for more detailsIncrease width for more details
← Efmarodocokin
Alfa reduces
riskEfmarodocokin
Alfa increases
risk →